ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
10 announcements
Cohance Lifesciences completed a USFDA inspection at its Jaggaiahpet API facility, receiving a Form 483 with five observations. The company has initiated corrective and preventive actions.
Cohance Lifesciences invested USD 10 million (₹95 Crore) into its subsidiary NJ Bio, Inc. to subscribe for new Compulsorily Convertible Preferred Stock.
Cohance Lifesciences Limited conducted its 8th Annual General Meeting on 17 September 2026. All resolutions proposed in the notice were passed by the requisite majority.
Cohance Lifesciences completed a USFDA inspection of its Shamshabad formulation plant, receiving a Form 483 with four observations. The company is initiating corrective measures.
Cohance Lifesciences announced a $18 million investment across two subsidiaries, NJ Bio and Aruka Bio, to strengthen its ADC strategy and commercial integration.
Cohance reported its lowest-ever quarter, plagued by customer shipment phasing and biotech funding delays, resulting in a 23% revenue decline. Management frames this as a trough, banking on H2 recovery through restocked commercial molecules.
Cohance reported a weak Q1FY27 with revenue at INR 4,223 Mn (-23.1% YoY) and adjusted EBITDA at INR 92 Mn (2.2% margin) due to phasing.
Cohance Lifesciences Ltd reported revenue from operations of ₹422.3 Cr (-23.1% YoY) and a net loss of ₹45.2 Cr for Q1 FY27.
Cohance Lifesciences Ltd reported revenue from operations of ₹619.1 Cr (-26.3% YoY) and net profit of ₹8.3 Cr (-92.9% YoY) for Q4 FY26.
Management is navigating a transition phase with significant revenue and margin pressure due to destocking and site disruptions. New CEO Umang Vohra focuses on embedding the company into global new drug value chains.